TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15843280

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 19
Study: 11800503

Group type: EXPERIMENTAL
Intervention: Amisulpride 50 mg o.d.
Number of subjects: 272

Group type: COMPARATOR
Intervention: Paroxetine 20 mg o.d.
Number of subjects: 272
Study: 10650023

Group type: EXPERIMENTAL
Intervention: Outpatient hysteroscopy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Day case hysteroscopy
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study: 8645650

Group type: EXPERIMENTAL
Intervention: Goserelin depot treatment for 8 weeks before endometrial resection
Number of subjects: 71

Group type: COMPARATOR
Intervention: Immediate surgery without pretreatment
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Goserelin treatment in women with adenomyosis
Number of subjects: 71
Study: 1534364

Group type: EXPERIMENTAL
Intervention: Combined bacterial and viral infection
Number of subjects: 271

Group type: COMPARATOR
Intervention: Only bacterial otitis
Number of subjects: 271

Group type: COMPARATOR
Intervention: Only viral infection
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Virus in middle ear fluid
Number of subjects: 271

Group type: COMPARATOR
Intervention: Virus only in nasal wash specimens or diagnosed by serologic studies
Number of subjects: 271
Study: 2410224

Group type: EXPERIMENTAL
Intervention: Contralateral application of a tone burst stimulus
Number of subjects: 0
Study: 31648967

Group type: EXPERIMENTAL
Intervention: DWI sequences
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: DWI+FLAIR sequences in combination
Number of subjects: 55
Study: 28834008

Group type: EXPERIMENTAL
Intervention: Insomnia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Insomnia (in patients aged <40 years)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Insomnia (duration <4 years)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Insomnia (duration 4 to 8 years)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Insomnia (duration >8 years)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Patients with insomnia
Number of subjects: 0
Study: 27094007

Group type: EXPERIMENTAL
Intervention: Thermometry plus mHealth (SMS and voice messaging)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Thermometry alone
Number of subjects: 0
Study: 22414889

Group type: EXPERIMENTAL
Intervention: Commercially available weight-loss regimen
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Unsupported dieting
Number of subjects: 45

Group type: COMPARATOR
Intervention: Non-dieting control group
Number of subjects: 45
Study: 21270715

Group type: COMPARATOR
Intervention: Surgical intervention for diabetic patients with IDH
Number of subjects: 199

Group type: COMPARATOR
Intervention: Surgical intervention for diabetic patients with SpS
Number of subjects: 199

Group type: COMPARATOR
Intervention: Surgical intervention for diabetic patients with DS
Number of subjects: 199

Group type: COMPARATOR
Intervention: Surgical intervention for nondiabetic patients with SpS
Number of subjects: 199

Group type: COMPARATOR
Intervention: Postoperative complications in diabetic patients with SpS
Number of subjects: 199

Group type: COMPARATOR
Intervention: Blood replacement in diabetic patients with DS
Number of subjects: 199
Study: 19386624

Group type: EXPERIMENTAL
Intervention: Assigned prenatal multivitamins
Number of subjects: 70

Group type: COMPARATOR
Intervention: Previous multivitamins
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Assigned prenatal multivitamins (for those who never took them)
Number of subjects: 70
Study: 16708045

Group type: EXPERIMENTAL
Intervention: Girls on the Move program (individually tailored computerized physical activity program plus nurse counseling)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group (received a handout listing physical activity recommendations)
Number of subjects: 77
Study: 15262844

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SESs)
Number of subjects: 1058

Group type: COMPARATOR
Intervention: Bare metal stents (BMS)
Number of subjects: 1058
Study: 11696804

Group type: EXPERIMENTAL
Intervention: Desmopressin 0.2 mg
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Desmopressin 0.4 mg
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Desmopressin 0.6 mg
Number of subjects: 193

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 193
Study: 9151010

Group type: EXPERIMENTAL
Intervention: External hip protectors
Number of subjects: 247
Study: 7953039

Group type: EXPERIMENTAL
Intervention: Family-based intervention including monthly 45-minute counselling sessions focused on management of social and occupational problems, medication management, family education, family group meetings, and crisis intervention.
Number of subjects: 63

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Family-based intervention
Number of subjects: 63
Study: 3069568

Group type: EXPERIMENTAL
Intervention: 2 g i.v. Cefotetan
Number of subjects: 144

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 144
Study: 29242972

Group type: EXPERIMENTAL
Intervention: Robot-assisted laparoscopic surgery
Number of subjects: 51

Group type: COMPARATOR
Intervention: Laparoscopic surgery
Number of subjects: 51
Study: 27032449

Group type: EXPERIMENTAL
Intervention: Internet-based problem solving therapy with weekly student support (n=136)
Number of subjects: 269

Group type: COMPARATOR
Intervention: Control group with self-help booklet (n=133)
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Internet-based problem solving therapy (n=136)
Number of subjects: 269
Study: 24173623

Group type: EXPERIMENTAL
Intervention: Sertraline 50 mg to a maximum of 200 mg/day
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Sertraline (in subset meeting DSM-IV criteria)
Number of subjects: 38
Study: 23690416

Group type: EXPERIMENTAL
Intervention: Experimental arm (chemotherapy based on ERCC1 and RRM1 levels)
Number of subjects: 275

Group type: COMPARATOR
Intervention: Control arm (gemcitabine/carboplatin)
Number of subjects: 275
Study: 20569705

Group type: EXPERIMENTAL
Intervention: Carperitide treatment (69.4%)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Angiotensin II receptor blockers (53.9%)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hospital stay
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Readmission rate
Number of subjects: 0
Study: 18157994

Group type: EXPERIMENTAL
Intervention: SDM group (physicians trained in SDM communication, access to computer-based information package)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Information-only group (standard physicians, only received information package)
Number of subjects: 85
Study: 20453720

Group type: EXPERIMENTAL
Intervention: Partner-delivered therapy (PDPT)
Number of subjects: 484

Group type: COMPARATOR
Intervention: Public health disease intervention (DIS)
Number of subjects: 484

Group type: COMPARATOR
Intervention: Self-referral of partners (PR)
Number of subjects: 484
Study: 16274808

Group type: EXPERIMENTAL
Intervention: Tinnitus retraining therapy (TRT)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Waiting list group
Number of subjects: 158

Group type: COMPARATOR
Intervention: Partially treated group (patients that refused prosthesis adaptation)
Number of subjects: 158
Study: 12111283

Group type: EXPERIMENTAL
Intervention: Highly trained professional rugby players (RP)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Highly trained triathletes (TA)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 36
Study: 9875635

Group type: EXPERIMENTAL
Intervention: HGV co-infection
Number of subjects: 89

Group type: COMPARATOR
Intervention: HCV infection without HGV co-infection
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: E2 antibodies presence
Number of subjects: 89
Study: 7979464

Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.2 mg/kg three times a day for two weeks)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (normal saline equivalent volumes)
Number of subjects: 16
Study: 2633666

Group type: EXPERIMENTAL
Intervention: Swan‐Ganz catheter with optic fibres emitting light characterized by three different wavelengths (Opticath Oximetrix)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Sat‐one Edwards catheter with two different wavelengths
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Oximetrix catheter
Number of subjects: 19

Group type: COMPARATOR
Intervention: Edwards catheter
Number of subjects: 19
Study: 11876688

Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 641

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 641
Study: 29440670

Group type: EXPERIMENTAL
Intervention: Conserved miRNAs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Novel miRNAs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Degradome sequencing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: qRT-PCR analysis
Number of subjects: 0
Study: 25826200

Group type: EXPERIMENTAL
Intervention: acting out terminology
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: clinical terms
Number of subjects: 110

Group type: COMPARATOR
Intervention: no-reading control
Number of subjects: 110
Study: 23864535

Group type: EXPERIMENTAL
Intervention: Polidocanol endovenous microfoam 0.5%
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Polidocanol endovenous microfoam 1.0%
Number of subjects: 232

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Polidocanol endovenous microfoam (both dosages)
Number of subjects: 232
Study: 22789766

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/vilanterol (FF/VI) 50/25 μg, 100/25 μg, and 200/25 μg, dosed once daily in the morning for 28 days
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 20308818

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acupoint stimulation (TEAS) at the P6 acupoint
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (nonacupoint site stimulation)
Number of subjects: 80
Study: 18534970

Group type: EXPERIMENTAL
Intervention: Group T (Th7-8)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Group L (L3-4)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Group C (Control)
Number of subjects: 54
Study: 15831640

Group type: EXPERIMENTAL
Intervention: glipizide 5 mg/day
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: metformin 500 mg/day
Number of subjects: 181

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 181
Study: 12182254

Group type: EXPERIMENTAL
Intervention: Piperacillin 12 g/tazobactam 1.5 g continuous infusion over 24 hours
Number of subjects: 11

Group type: COMPARATOR
Intervention: Piperacillin 6 g/tazobactam 0.75 g continuous infusion over 24 hours
Number of subjects: 11

Group type: COMPARATOR
Intervention: Piperacillin 3 g/tazobactam 0.375 g q6h for 24 hours
Number of subjects: 11

Group type: COMPARATOR
Intervention: Piperacillin 6.75 g continuous infusion over 24 hours
Number of subjects: 11
Study: 10564834

Group type: EXPERIMENTAL
Intervention: Carbon particulates suspended in PFD
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: PFD formulation
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline formulation
Number of subjects: 12
Study: 8719690

Group type: EXPERIMENTAL
Intervention: Apraclonidine hydrochloride 0.5%
Number of subjects: 174

Group type: COMPARATOR
Intervention: Placebo (apraclonidine's vehicle)
Number of subjects: 174
Study: 2110206

Group type: EXPERIMENTAL
Intervention: Fluvoxamine with antiexposure (F)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fluvoxamine with exposure (Fe)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Placebo with exposure (Pe)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fluvoxamine (F)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fluvoxamine (Fe)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fluvoxamine (F, Fe)
Number of subjects: 60
Study: 6777131

Group type: EXPERIMENTAL
Intervention: Metoclopramide (administered orally in a double-blind fashion)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Healthy controls (no intervention)
Number of subjects: 13
Study: 31253407

Group type: EXPERIMENTAL
Intervention: Iron-fortified formula (12 mg/L)
Number of subjects: 405

Group type: COMPARATOR
Intervention: Low-iron formula (2.3 mg/L)
Number of subjects: 405
Study: 30239384

Group type: EXPERIMENTAL
Intervention: Lorazepam in combination with haloperidol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Benzodiazepines (scheduled doses or continuous infusion)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Benzodiazepines
Number of subjects: 0
Study: 25951791

Group type: EXPERIMENTAL
Intervention: Levocetirizine and Imipramine
Number of subjects: 166

Group type: COMPARATOR
Intervention: Levocetirizine
Number of subjects: 166
Study: 24848008

Group type: EXPERIMENTAL
Intervention: Intra-operative passive movement
Number of subjects: 42

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 42
Study: 21114797

Group type: EXPERIMENTAL
Intervention: Group-based programme (GRP)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Monitored home-based programme (MHP)
Number of subjects: 42
Study: 20048189

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with cisplatin and fluorouracil
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: TP53 mutations
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Nonfunctional TP53 mutations
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: TP53 mutation
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Nonfunctional TP53 mutation
Number of subjects: 53
Study: 18067659

Group type: EXPERIMENTAL
Intervention: Usual care plus antidepressants (UCandAD)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Usual care alone (UCnoAD)
Number of subjects: 181
Study: 16279567

Group type: EXPERIMENTAL
Intervention: 0.1% olopatadine hydrochloride ophthalmic solution, administered twice daily for 2 weeks in addition to nasal or systemic antiallergy medication.
Number of subjects: 200

Group type: COMPARATOR
Intervention: No ocular therapy (control group), using only previously prescribed antiallergy medication for 2 weeks.
Number of subjects: 200
Study: 11868619

Group type: EXPERIMENTAL
Intervention: Participants exposed to PTP biased against the defendant
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Judicial admonition before and after trial evidence
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control article
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PTP biased against the plaintiff
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Judicial admonition after trial only or not at all
Number of subjects: 0
Study: 11157288

Group type: EXPERIMENTAL
Intervention: System-change training model intervention
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 12
Study: 9878108

Group type: EXPERIMENTAL
Intervention: Expected versions of passages
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Unexpected (garden path) versions of passages
Number of subjects: 3
Study: 8061842

Group type: EXPERIMENTAL
Intervention: Spirapril 3 mg once daily
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Spirapril 12 mg once daily
Number of subjects: 52
Study: 3141101

Group type: EXPERIMENTAL
Intervention: 150 ml of a fermented milk test product supplying at least 2 X 10(9) live Lactobacillus acidophilus bacteria daily and 6.5% lactulose as substrate for the bacteria.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Dietary counselling only (Control group).
Number of subjects: 24
Study: 766826

Group type: EXPERIMENTAL
Intervention: Dexon (polyglycolic acid) sutures
Number of subjects: 51

Group type: COMPARATOR
Intervention: Silk sutures
Number of subjects: 51

Group type: COMPARATOR
Intervention: Collagen sutures
Number of subjects: 51
Study: 31726193

Group type: EXPERIMENTAL
Intervention: Individual-focused lifestyle intervention program for 12 months
Number of subjects: 635

Group type: EXPERIMENTAL
Intervention: Peer-to-peer-based lifestyle intervention program for 12 months
Number of subjects: 635

Group type: EXPERIMENTAL
Intervention: High-adherence participants to the intervention
Number of subjects: 635

Group type: EXPERIMENTAL
Intervention: Low-adherence participants to the intervention
Number of subjects: 635

Group type: EXPERIMENTAL
Intervention: Knowledge of presence of atherosclerosis
Number of subjects: 635

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 635

Group type: EXPERIMENTAL
Intervention: Sustainability of intervention
Number of subjects: 635
Study: 30605695

Group type: COMPARATOR
Intervention: Standard bulbar urethroplasty (Group I, n=25)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Bulbar urethroplasty with preservation of bulbospongiosus muscle and nerve (Group II, n=25)
Number of subjects: 50
Study: 28279492

Group type: EXPERIMENTAL
Intervention: COX-1 inhibitor reactions
Number of subjects: 12
Study: 25289793

Group type: EXPERIMENTAL
Intervention: Nitrate gels (NIT) + UV‐A
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: NIT + SHAM
Number of subjects: 9

Group type: COMPARATOR
Intervention: PLA + UV‐A
Number of subjects: 9

Group type: COMPARATOR
Intervention: PLA + SHAM
Number of subjects: 9
Study: 22520278

Group type: EXPERIMENTAL
Intervention: Oral cannabis brief intervention (C-O)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Written cannabis brief intervention (C-W)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Oral health brief intervention (H-O)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Written health brief intervention (H-W)
Number of subjects: 134
Study: 21597242

Group type: EXPERIMENTAL
Intervention: Anisodamine
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 126
Study: 19339720

Group type: EXPERIMENTAL
Intervention: Cetuximab plus FOLFIRI
Number of subjects: 1198

Group type: COMPARATOR
Intervention: FOLFIRI alone
Number of subjects: 1198

Group type: EXPERIMENTAL
Intervention: Cetuximab plus FOLFIRI (wild-type KRAS)
Number of subjects: 1198
Study: 16111894

Group type: EXPERIMENTAL
Intervention: Walking in shallow water
Number of subjects: 10

Group type: COMPARATOR
Intervention: Walking on land
Number of subjects: 10
Study: 15517844

Group type: EXPERIMENTAL
Intervention: Sertraline and clonazepam
Number of subjects: 37

Group type: COMPARATOR
Intervention: Sertraline and placebo
Number of subjects: 37
Study: 11519768

Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2% BID
Number of subjects: 159

Group type: COMPARATOR
Intervention: Betaxolol 0.25% BID
Number of subjects: 159
Study: 9086143

Group type: EXPERIMENTAL
Intervention: CVD103‐HgR with chloroquine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CVD103‐HgR with mefloquine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ty21a with proguanil
Number of subjects: 0
Study: 8441108

Group type: EXPERIMENTAL
Intervention: Intravenously administered theophylline (aminophylline)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 2874906

Group type: EXPERIMENTAL
Intervention: GRF 1-29 (1 microgram/kg i.v.) with pirenzepine (0.6 mg/kg, i.v.)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: TRH (200 micrograms/kg, i.v.) with pirenzepine (0.6 mg/kg, i.v.)
Number of subjects: 8

Group type: COMPARATOR
Intervention: GRF 1-29 (1 microgram/kg i.v.) without pirenzepine
Number of subjects: 8

Group type: COMPARATOR
Intervention: TRH (200 micrograms/kg, i.v.) without pirenzepine
Number of subjects: 8
Study: 30789857

Group type: EXPERIMENTAL
Intervention: External attentional focus
Number of subjects: 17

Group type: COMPARATOR
Intervention: Neutral attentional focus
Number of subjects: 17
Study: 29427527

Group type: EXPERIMENTAL
Intervention: Oral antioxidants (vitamins C and E and α‐lipoic acid)
Number of subjects: 21
Study: 27861342

Group type: EXPERIMENTAL
Intervention: Intensive medical therapy (diet and exercise counseling)
Number of subjects: 316

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 316
Study: 24552199

Group type: EXPERIMENTAL
Intervention: Couples-based HIV counseling and testing (CHCT) intervention comprising two group sessions and four couples' counseling sessions.
Number of subjects: 700

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 700
Study: 22615190

Group type: EXPERIMENTAL
Intervention: cilostazol plus l-carnitine 1 g twice-daily
Number of subjects: 145

Group type: COMPARATOR
Intervention: cilostazol alone (placebo)
Number of subjects: 145
Study: 19880141

Group type: EXPERIMENTAL
Intervention: EHCF + LGG (Nutramigen LGG)
Number of subjects: 30

Group type: COMPARATOR
Intervention: EHCF - LGG (Nutramigen)
Number of subjects: 30
Study: 17702897

Group type: EXPERIMENTAL
Intervention: Eculizumab treatment
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Eculizumab treatment in antithrombotic-treated patients (n = 103)
Number of subjects: 195
Study: 15998952

Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy screening
Number of subjects: 77465

Group type: EXPERIMENTAL
Intervention: Follow-up lower endoscopic procedures
Number of subjects: 77465

Group type: EXPERIMENTAL
Intervention: Follow-up lower endoscopy for larger polyps (> or = 0.5 cm)
Number of subjects: 77465

Group type: EXPERIMENTAL
Intervention: Follow-up lower endoscopy for smaller polyps (< 0.5 cm)
Number of subjects: 77465

Group type: EXPERIMENTAL
Intervention: Colorectal cancer detection rates per 1000 screened
Number of subjects: 77465

Group type: EXPERIMENTAL
Intervention: Advanced adenoma detection rates per 1000 screened
Number of subjects: 77465

Group type: EXPERIMENTAL
Intervention: Colorectal cancer or any adenoma detection rates per 1000 screened
Number of subjects: 77465

Group type: EXPERIMENTAL
Intervention: Stage of colorectal adenocarcinoma at diagnosis
Number of subjects: 77465
Study: 12636960

Group type: EXPERIMENTAL
Intervention: Polyurethane condom
Number of subjects: 901

Group type: COMPARATOR
Intervention: Latex condom
Number of subjects: 901
Study: 10496251

Group type: EXPERIMENTAL
Intervention: Risperidone (mean dose 1.1 mg/d)
Number of subjects: 344

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Haloperidol (mean dose 1.2 mg/d)
Number of subjects: 344
Study: 9185259

Group type: EXPERIMENTAL
Intervention: Intramuscular anti-snake venom administration as a first aid measure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard hospital management alone
Number of subjects: 0
Study: 1684197

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Parenterally-administered cephalosporin
Number of subjects: 0